期刊文献+

细胞间黏附分子1在溃疡性结肠炎诊治中的临床意义 被引量:3

Clinical significance of intercellular adhesion molecule-1 in ulcerative colitis
原文传递
导出
摘要 目的探讨血清细胞间黏附分子1(ICAM-1)水平在溃疡性结肠炎(UC)中的临床意义。方法收集30例UC患者(UC组)及30例正常者(C组)的血清,分别以ELISA法及免疫速率比浊法检测血清ICAM-1及C反应蛋白(CRP)水平。结果UC组ICAM-1的水平明显高于C组(P<0.05);同一患者UC活动期ICAM-1高于缓解期(P<0.05);ICAM-1水平升高与UC疾病活动度的严重程度呈正相关(P<0.05),而与UC发生部位无关(P>0.05);ICAM-1与CRP有良好一致性(r=0.8)。结论UC患者血清ICAM-1水平升高与疾病活动度呈正相关,可作为UC疾病活动度和判断治疗效果的一个客观指标。 Objective To study the clinical significance of the serum intercellular adhesion molecule-1 (ICAM-1) level in the patients with ulcerative colitis(UC). Methods Serum ICAM-1 and CRP of 30 UC patients and 30 normal controls were detected with ELISA and immunization rate turbidimetry. Results Serum ICAM-1 level in UC patients was significantly higher than that in normal controls (P〈0.05). Serum ICAM-1 level in the active phase was significantly higher than that in the remission phase in the same patients (P〈0.05). ICAM-1 was positively correlated with the severity of the activity of UC (P〈0. 05), which was not correlated with lesion locations (P〉 0. 05). There was a good consistency between ICAM-1 and CRP (r= 0.8). Conclusion Serum ICAM-1 level was higher in UC patients and positively correlated with disease severity,which may be taken as one of the objective indicators for evaluating the UC activity and therapeutic efficacy.
出处 《江苏医药》 CAS CSCD 北大核心 2009年第6期649-651,共3页 Jiangsu Medical Journal
关键词 溃疡性结肠炎 细胞间黏附分子1 Ulcerative colitis Intercellular adhesion molecule-1
  • 相关文献

参考文献5

二级参考文献74

  • 1陈治水,危北海,张万岱.溃疡性结肠炎中西医结合诊治方案[J].世界华人消化杂志,2004,12(11):2690-2693. 被引量:47
  • 2林如峰,陆化,沈文怡,刘澎,王永韧,汪承亚,李建勇.蛋白酶体抑制剂PS-341对多发性骨髓瘤间充质干细胞IL-1β表达的影响[J].江苏医药,2006,32(4):337-339. 被引量:3
  • 3江学良 权启镇 等.炎症性肠病患者外周血可溶性CD44v6检测[J].世界华人消化杂志,1999,7:1028-1028.
  • 4潘国宗 刘彤华 见:潘国宗 曹世植9. 主编.溃疡性结肠炎[A].见:潘国宗,曹世植9.,主编.现代胃肠病学.第Ⅰ版[C].北京:科学出版社,1994.1246-1247.
  • 5潘国宗 刘彤华.Crohn病[A].见:潘国宗 曹世植 主编.现代胃肠病学[C].北京:科学出版社,1994.1154.
  • 6Stack WA, Mann SD, Roy AJ, Heath P, Sopwith M, Freeman J,Holmes G, Long R, Forbes A, Kamm MA. Randomised controlled trial of CDP571 antibody to tumour necrosis factoralpha in Crohn's disease. Lancet 1997;349:521-524.
  • 7Vasiliauskas EA, Kam LY, Abreu-Martin MT, Hassard PV,Papadakis KA, Yang H, Zeldis JB, Targan SR. An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease. Gastroenterology 1999;117:1278-1287.
  • 8Ehrenpreis ED, Kane SV, Cohen LB, Cohen RD, Hanauer SB.Thalidomide therapy for patients with refractory Crohn's disease:an open-label trial. Gastroenterology 1999;117:1271-1277.
  • 9Facchini S, Candusso M, Martelossi S, Liubich M, Panfili E,Ventura A. Efficacy of long-term treatment with thalidomide in children and young adults with Crohn disease: preliminary results. J Pediatr Gastroenterol Nutr 2001;32:178-181.
  • 10Bauditz J, Wedel S, Lochs H. Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease. Gut 2002;50:196-200.

共引文献775

同被引文献45

引证文献3

二级引证文献99

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部